Munich‑based Tubulis expanded its Series C financing to $401 million to accelerate development of its next‑generation antibody‑drug conjugate (ADC) platform. The company said the fresh capital will fund advanced preclinical programs and scale up payload and linker innovations designed to broaden ADC therapeutic index. Investors view the raise as validation of ADC technology maturation and the market’s appetite for improved targeting and payload chemistries. Tubulis’ funding positions it to advance multiple clinical candidates and to compete for discovery partnerships with established biopharma firms.